Business
Case Report on Clinical Value of IB Software
Case Report on Clinical Value of IB Software.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \n \n \n RNS Number : 7098N\n IQ-AI Limited\n 01 October 2021\n \n \n \n \n 1 October 2021\n \n \n IQ-AI Limited \n \n \n (\"IQ-AI\" or the \"Company\")\n \n \n PUBLISHED NEUROSURGERY CASE REPORT UNDERSCORES CLINICAL VALUE OF IB SOFTWARE\n \n \n AFFILIATED HOSPITAL PURCHASES IB CLINIC FOR AUTOMATED ANALYSIS\n \n \n \n Milwaukee - IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF)\n \n , a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors. \n \n \n The on-going challenge with the treatment of brain tumors is that new or recurrent tumor can appear the same as treatment effect on traditional postcontrast magnetic resonance imaging (MRI) images. Today's standard of care requires either many weeks of follow-up imaging or an invasive surgical biopsy to confirm diagnosis. Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, has developed and validated a non-invasive, timely and quantitative imaging solution that addresses this issue.\n \n \n For the published study, IB Clinic®, which is IB's non-invasive, neuro-oncology platform, was used to distinguish brain tumor tissue from treatment effect. The results explained the discordance between the intraoperative assessment and the pathologic diagnosis suggesting that IB Clinic should be routinely used to optimize surgical guidance and pathologic diagnosis, which in turn would lead to optimized treatment management and patient outcomes.\n \n \n \"We are relying on FTB maps more routinely in our clinical practice as well as our weekly comprehensive multidiscipline brain tumor boards. They have proven to provide information that can help interpret MRI findings and optimize treatment for our patients,\" said Dr. Jennifer Connelly, MD, Associate Professor of Neurology and Co-Director of the Neuro-oncology Program at Froedtert and the Medical College of Wisconsin and lead author of the paper. \n \n \n The case report authors are clinicians and scientists from the Medical College of Wisconsin (MCW, Milwaukee, WI), which is affiliated with Froedtert Health (Milwaukee, WI). For more than a decade, Froedtert Health's radiology department have used IB software for analyzing magnetic...